98 related articles for article (PubMed ID: 35638777)
1. A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints.
Gupta V; Yu KC; Pogue JM; Watts JA; Clancy CJ
Microbiol Spectr; 2022 Jun; 10(3):e0115822. PubMed ID: 35638777
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and characteristics of ertapenem-mono-resistant isolates among carbapenem-resistant Enterobacterales in China.
Wang Y; Hu H; Shi Q; Zhang P; Zhao D; Jiang Y; Yu Y
Emerg Microbes Infect; 2024 Dec; 13(1):2332658. PubMed ID: 38517707
[TBL] [Abstract][Full Text] [Related]
3. Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022.
Wise MG; Karlowsky JA; Mohamed N; Hermsen ED; Kamat S; Townsend A; Brink A; Soriano A; Paterson DL; Moore LSP; Sahm DF
J Glob Antimicrob Resist; 2024 Jun; 37():168-175. PubMed ID: 38608936
[TBL] [Abstract][Full Text] [Related]
4. Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales.
Tamma PD; Harris PNA; Mathers AJ; Wenzler E; Humphries RM
Clin Infect Dis; 2023 Nov; 77(11):1585-1590. PubMed ID: 36001445
[TBL] [Abstract][Full Text] [Related]
5. Overview of Changes to the Clinical and Laboratory Standards Institute
Humphries R; Bobenchik AM; Hindler JA; Schuetz AN
J Clin Microbiol; 2021 Nov; 59(12):e0021321. PubMed ID: 34550809
[TBL] [Abstract][Full Text] [Related]
6. Carbapenem non-susceptibility overcalling by BD phoenix NMIC-500 panel.
Yoo IY; Ha SI; Kim SW; Kim JK; Seok HS; Park YJ
J Infect Chemother; 2024 Apr; ():. PubMed ID: 38570137
[TBL] [Abstract][Full Text] [Related]
7. Possible impact of revisions in disc diffusion breakpoints for aminoglycosides and piperacillin/tazobactam in the 33rd edition of CLSI M100 document on clinical reporting and use in Indian settings with low susceptibility.
Aggarwal P; Saxena S; Nagi N
Indian J Med Microbiol; 2024; 49():100602. PubMed ID: 38697481
[TBL] [Abstract][Full Text] [Related]
8. Using the CLSI rAST breakpoints of Enterobacterales in positive blood cultures.
Deng J; An Y; Kang M
Diagn Microbiol Infect Dis; 2024 Jul; 109(3):116335. PubMed ID: 38703531
[TBL] [Abstract][Full Text] [Related]
9. Amoxicillin-clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute.
Narayanan N; Mathers AJ; Wenzler E; Moore NM; Giske CG; Mendes RE; Edelstein PH
Clin Infect Dis; 2024 Apr; ():. PubMed ID: 38626241
[TBL] [Abstract][Full Text] [Related]
10. Comparison of carbapenem MIC for NDM-producing Enterobacterales by different AST methods.
Lee ALH; Leung ECM; Chow VCY
JAC Antimicrob Resist; 2024 Apr; 6(2):dlae028. PubMed ID: 38686026
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Doripenem, Meropenem, and Imipenem against Respiratory Isolates of
Negi A; Anand M; Singh A; Kumar A; Sahu C; Prasad KN
Indian J Crit Care Med; 2017 Oct; 21(10):703-706. PubMed ID: 29142383
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Intravenous Fosfomycin Disodium Dosing Regimens in Critically Ill Patients for Treatment of Carbapenem-Resistant Enterobacterales Infections Using Monte Carlo Simulation.
Leelawattanachai P; Wattanavijitkul T; Paiboonvong T; Plongla R; Chatsuwan T; Usayaporn S; Nosoongnoen W; Montakantikul P
Antibiotics (Basel); 2020 Sep; 9(9):. PubMed ID: 32961833
[TBL] [Abstract][Full Text] [Related]
13. Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012.
Rennie RP; Jones RN
Can J Infect Dis Med Microbiol; 2014 Sep; 25(5):285-7. PubMed ID: 25371693
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin/tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing.
Lodise TP; Bhavnani SM; Ambrose PG; Sader HS; Andes DR; Pogue JM
Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38902929
[TBL] [Abstract][Full Text] [Related]
15. Direct prediction of antimicrobial resistance in
Cao L; Yang H; Huang Z; Lu C; Chen F; Zhang J; Ye P; Yan J; Zhang H
Front Microbiol; 2024; 15():1413434. PubMed ID: 38903781
[TBL] [Abstract][Full Text] [Related]
16. Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study.
Walker MK; Diao G; Warner S; Babiker A; Neupane M; Strich JR; Yek C; Kadri SS;
Lancet Infect Dis; 2024 Apr; ():. PubMed ID: 38679036
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Activity of Pentamidine Alone and in Combination with Antibiotics against Multidrug-Resistant Clinical
Herrera-Espejo S; Cebrero-Cangueiro T; Labrador-Herrera G; Pachón J; Pachón-Ibáñez ME; Álvarez-Marín R
Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33317111
[TBL] [Abstract][Full Text] [Related]
18. Microscopic characterization of Pseudomonas Aeruginosa confines separate from clinical cases by testing RAPD-PCR method.
Mahmmudi Z; Emami A; Gorzin AA
J Med Life; 2015; 8(Spec Iss 4):319-323. PubMed ID: 28316751
[TBL] [Abstract][Full Text] [Related]
19. Multiplexed paper-based assay for personalized antimicrobial susceptibility profiling of Carbapenem-resistant Enterobacterales performed in a rechargeable coffee mug.
Oeschger T; Kret L; Erickson D
Sci Rep; 2022 Jul; 12(1):11990. PubMed ID: 35835831
[TBL] [Abstract][Full Text] [Related]
20. Hospital mortality and length of stay associated with
Cooper L; Yu K; Van Benten K; Patkar A; Ye G; Gregory S; Ai C; Gupta V
Microbiol Spectr; 2024 Jul; ():e0040224. PubMed ID: 38953323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
